Study S003332

A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of Multiple Dose Regimens of Once-Weekly Switching to Once-Monthly MET097 in Participants With Obesity or Overweight (VESPER-3)

ClinicalTrials.gov record

Registration

Registration: NCT06973720
Acronym: VESPER-3
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 268
Start: 2025-04-07
Primary completion: 2025-12-16
Lead sponsor: Pfizer
Conditions: Obesity; Overweight or Obesity
Interventions: DRUG:MET097; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:C6491006

Registered primary outcomes

Percent change from baseline in body weight at Week 28 [Baseline (Week 0) through Week 28 (Day 197)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.